Evidence map›Paper›PMID 39917302›Full record

ReviewFrontiers in immunology2025

Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review.

Xiaojing Liang, Guoqing Xu, Jisong Zhang, Li Xu, Liangliang Dong, Xiaoyue Wang, Weidong Han, Enguo Chen

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaojing Liang *Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Guoqing Xu *Department of Pulmonary and Critical Care Medicine, National Regional Medical Center, Zhejiang University Sir Run Run Shaw Alaer Hospital, Alaer, Xinjiang, China.
Jisong ZhangDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Li XuDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Liangliang DongDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Xiaoyue WangDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Weidong HanDepartment of Medical Oncology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Enguo ChenDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary pulmonary choriocarcinoma (PPC) is an extremely rare malignant cancer in men with no clinical guidelines for the treatment. Cytotoxic chemotherapy has a limited effect on the prognosis of PPC. Recently, immune checkpoint inhibitors (ICIs) have shown promising treatment effectiveness. A literature review revealed that a combination of chemotherapy and ICIs could prolong the survival time of PPC patients. Herein, we report a 67-year-old man with a cough, expectoration, and blood in the sputum, presenting with a mass in the lower lobe of the right lung. The hematoxylin and eosin staining and immunohistochemical profile of the primary lesion showed features of choriocarcinoma, accompanied by elevations in serum human chorionic gonadotropin (HCG) levels. Programmed death-ligand 1 (PD-L1) expression was positive (70%) in the 22C3 assay. He received a combination of cisplatin, etoposide, paclitaxel, and sintilimab. Four months after the treatment began, chest computed tomography (CT) showed significant mass reduction. Therefore, ICIs may be a promising therapy option for patients with PPC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChoriocarcinomaLung NeoplasmsAgedCisplatinEtoposideHumansImmune Checkpoint InhibitorsMalePaclitaxelTreatment OutcomeAntibodies, Monoclonal, HumanizedCisplatinEtoposideImmune Checkpoint InhibitorsPaclitaxelsintilimabchemotherapyhuman chorionic gonadotropinimmune checkpoint inhibitorsprimary pulmonary choriocarcinomaprogrammed death-ligand 1

Identifiers

PMID39917302
PMCPMC11799555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.